{"filing":{"accession_number":"0001193125-26-338321","cik":"0001661181","ticker":"ORGO","company_name":"Organogenesis Holdings Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d117484d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661181/000119312526338321/d117484d8k.htm"},"events":[{"id":24626,"run_id":22326,"accession_number":"0001193125-26-338321","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Organogenesis entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026, authorizing the sale of up to $75 million in Class A common stock through agents BTIG and Citizens JMP Securities. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a common capital-raising mechanism at small- and mid-cap issuers. The material amount ($75M) and the explicit authorization to sell shares \"from time to time\" through registered agents make this a dilutive issuance event.","company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25247,"accession_number":"0001193125-26-338321","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Organogenesis entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026, authorizing the sale of up to $75 million in Class A common stock through agents BTIG and Citizens JMP Securities. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a common capital-raising mechanism at small- and mid-cap issuers. The material amount ($75M) and the explicit authorization to sell shares \"from time to time\" through registered agents make this a dilutive issuance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:25:04.513634+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25247,"accession_number":"0001193125-26-338321","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Organogenesis entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026, authorizing the sale of up to $75 million in Class A common stock through agents BTIG and Citizens JMP Securities. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a common capital-raising mechanism at small- and mid-cap issuers. The material amount ($75M) and the explicit authorization to sell shares \"from time to time\" through registered agents make this a dilutive issuance event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:25:04.513634+00:00","company_name":"Organogenesis Holdings Inc.","ticker":"ORGO","filing_date":"2026-08-06"}]}